Lurasidone Hydrochloride Tablet
Product Images NDC 82804-215

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 82804-215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-215-30 (Image 01)

Label for Lurasidone HCl 20 mg tablets by Proficient Rx LP, packaged as 30 tablets. The label includes a barcode, NDC 82804-215-30, and states the medication is prescription only. Tablets are described as white to off-white, round, biconvex, film-coated with debossed markings. Manufactured by Aurobindo Pharma Limited, Hyderabad, India. Storage instructions and caution to keep medication out of children's reach are also present.*

FDA Label Image

Figure 1: Impact Of Other Drugs On Lurasidone Hydrochloride Pharmacokinetics (Lurasidone Fig1)

A pharmacokinetic (PK) interaction plot showing fold change and 90% confidence intervals in Cmax and AUC of lurasidone when coadministered with various interacting drugs: strong CYP3A4 inhibitor ketoconazole (400 mg/day), moderate CYP3A4 inhibitor diltiazem (240 mg/day), strong CYP3A4 inducer rifampin (600 mg/day), and lithium (600 mg BID). The x-axis represents fold change relative to lurasidone alone, ranging from -4 to 4.*

FDA Label Image

Figure 2: Impact Of Lurasidone Hydrochloride On Other Drugs (Lurasidone Fig2)

A chart illustrating fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, Ctrough) of various interacting drugs relative to Lurasidone Hydrochloride alone. It includes data for P-gp substrates (Digoxin), CYP3A4 substrates (Midazolam), oral contraceptives (Ethinyl Estradiol, Norethindrone), and Lithium, showing their changes in exposure when co-administered.*

FDA Label Image

Figure 3: Impact Of Other Patient Factors On Lurasidone Hydrochloride Pharmacokinetics (Lurasidone Fig3)

A chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Lurasidone Hydrochloride in populations with varying degrees of renal and hepatic impairment, as well as by gender and race. The horizontal axis shows change relative to reference values, with points and error bars indicating variability in each subgroup.*

FDA Label Image

Chemical Structure (Lurasidone Str)

Chemical structure diagram of lurasidone hydrochloride, showing its complex molecular arrangement including multiple rings and heteroatoms, consistent with the drug's active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.